

The Landmark RBX2660 Clinical Trial Program

Ferring and Rebiotix, a Ferring Company, have the largest and most robust clinical trial program ever conducted in microbiome-based therapeutics. The pivotal Phase 3 results for investigational RBX2660 are the first of its kind to demonstrate efficacy as early as first recurrence of *C. difficile* infection (CDI).

Details Of RBX2660 Clinical Trials:

World's most robust clinical program in microbiome-based therapeutics

3

Phase 2 trials, including a randomized double-blind placebo controlled Phase 2B trial

2

Phase 3 trials, including the pivotal PUNCH™ CD3 trial and PUNCH™ CD3 Open-Label study with expanded patient inclusion criteria (presented at DDW® 2021)

1

Retrospective assured active treatment (AAT) trial

The Decade-long Development Program Has:

> 1,000
patients enrolled



24 months of patient evaluation from two studies – longest follow-up period of any microbiome-based therapeutic

The Program Is:

Designed to be representative of people physicians treat everyday



The only one:

- utilizing the same manufacturing process for product through the entire clinical program
- showing:
 - repeated efficacy over placebo + standard of care
 - consistent safety across the clinical trial program

CDI Is A Major Health Threat

CDI is an urgent public health threat requiring immediate action.

Kills ~30K people in the U.S. each year

Approx. 500,000 cases a year in the U.S.

CDI recurs in up to 35% of people within 8 weeks after first diagnosis

Antibiotics – which are the standard of care for treatment of CDI – treat the disease but also are the primary risk factor for a vicious cycle of recurrence, causing a significant burden for patients suffering from this debilitating and potentially deadly illness.

To learn more, visit www.ferringusa.com and follow us on Twitter and LinkedIn @FerringMBiome.

FERRING
PHARMACEUTICALS

Microbiome
Therapeutics
Development